WEGOVY Drug Patent Profile

Which patents cover Wegovy, and what generic alternatives are available?

Wegovy is a drug marketed by Novo and is included in two NDAs. There are eighteen patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in WEGOVY is semaglutide. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the semaglutide profile page.

DrugPatentWatch^® Generic Entry Outlook for Wegovy

Wegovy was eligible for patent challenges on December 5, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 19, 2029. This may change due to patent challenges or generic licensing.

There have been twenty-five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (semaglutide), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for WEGOVY

US Patents:	18
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	16
Clinical Trials:	28
Patent Applications:	1,820
Drug Prices:	Drug price information for WEGOVY
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for WEGOVY
What excipients (inactive ingredients) are in WEGOVY?	WEGOVY excipients list
DailyMed Link:	WEGOVY at DailyMed

See drug prices for WEGOVY

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for WEGOVY

Constraining patent/regulatory exclusivity:

NEW STRENGTH

NDA:

215256

Dosage:

SOLUTION;SUBCUTANEOUS

Constraining patent/regulatory exclusivity:

11,382,957

NDA:

218316

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for WEGOVY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Metis Foundation	PHASE3
University of Colorado, Denver	PHASE3
University of Minnesota	PHASE3

See all WEGOVY clinical trials

Pharmacology for WEGOVY

Drug Class	GLP-1 Receptor Agonist
Mechanism of Action	Glucagon-like Peptide-1 (GLP-1) Agonists

Paragraph IV (Patent) Challenges for WEGOVY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
WEGOVY	Tablets	semaglutide	1.5 mg, 4 mg and 9 mg	218316	1	2026-03-11

US Patents and Regulatory Information for WEGOVY

WEGOVY is protected by twenty US patents and four FDA Regulatory Exclusivities.

This potential generic entry date is based on NEW STRENGTH.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-004	Jun 4, 2021		RX	Yes	Yes	9,764,003
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-005	Jun 4, 2021		RX	Yes	Yes
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-008	May 5, 2026		RX	Yes	Yes	11,478,533
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-002	Jun 4, 2021		RX	Yes	Yes
Novo	WEGOVY HD	semaglutide	SOLUTION;SUBCUTANEOUS	215256-006	Mar 19, 2026		RX	Yes	Yes	10,888,605		Y

Expired US Patents for WEGOVY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-005	Jun 4, 2021	8,536,122
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-003	Jun 4, 2021	8,536,122
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-001	Jun 4, 2021	8,536,122
Novo	WEGOVY	semaglutide	SOLUTION;SUBCUTANEOUS	215256-004	Jun 4, 2021	8,536,122
Novo	WEGOVY	semaglutide	TABLET;ORAL	218316-003	Dec 22, 2025	8,536,122

EU/EMA Drug Approvals for WEGOVY

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novo Nordisk A/S	Wegovy	semaglutide	EMEA/H/C/005422Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of- ≥30 kg/m² (obesity), or- ≥27 kg/m² to	Authorised	no	no	no	2022-01-06
Novo Nordisk A/S	Ozempic	semaglutide	EMEA/H/C/004174Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindications;in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.	Authorised	no	no	no	2018-02-08
Novo Nordisk A/S	Rybelsus	semaglutide	EMEA/H/C/004953Rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin combination with other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.	Authorised	no	no	no	2020-04-03

International Patents for WEGOVY

When does loss-of-exclusivity occur for WEGOVY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

Hungary

Japan

Lithuania

Mexico

Poland

Portugal

Russian Federation

San Marino

Serbia

Slovenia

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering WEGOVY around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	112480
Australia	2018321157
Australia	2024204151
Brazil	112020002804
Canada	3082033

Supplementary Protection Certificates for WEGOVY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1863839	300936	Netherlands		PRODUCT NAME: SEMAGLUTIDE; REGISTRATION NO/DATE: EU/1/17/1251 20180208
1863839	2018C/016	Belgium		PRODUCT NAME: OZEMPIC - SEMAGLUTIDE; AUTHORISATION NUMBER AND DATE: EU/1/17/1251 20180212
1863839	CR 2018 00019	Denmark		PRODUCT NAME: SEMAGLUTID; REG. NO/DATE: EU/1/17/1251 20180212
1863839	122018000075	Germany		PRODUCT NAME: OZEMPIC-SEMAGLUTID; REGISTRATION NO/DATE: EU/1/17/1251 20180208
1863839	2018/017	Ireland		PRODUCT NAME: OZEMPIC-SEMAGLUTIDE; REGISTRATION NO/DATE: EU/1/17/1251 20180208

Last updated: August 27, 2026

Wegovy is Novo Nordisk's leading obesity franchise and one of the pharmaceutical industry's fastest-growing products. Sales increased from DKK 31.3 billion in 2023 to approximately DKK 58.2 billion in 2024, while demand continued to exceed supply in several markets. The commercial outlook remains strong, but pricing pressure, Eli Lilly's Zepbound, manufacturing capacity, payer restrictions, and eventual semaglutide patent expiry will determine the product's long-term value.

Wegovy Market Dynamics, Financial Trajectory, Patents, Competition, and Generic Risk

What is Wegovy and how does it work?

Wegovy is a once-weekly injectable formulation of semaglutide, a glucagon-like peptide-1, or GLP-1, receptor agonist. Novo Nordisk markets it for chronic weight management in combination with reduced-calorie diet and increased physical activity.

The approved maintenance dose is 2.4 mg once weekly for most adults and eligible adolescents. Wegovy slows gastric emptying, increases satiety, and reduces appetite. Its principal commercial differentiation is the combination of substantial weight loss, weekly dosing, and cardiovascular-outcomes data.

The U.S. Food and Drug Administration approved Wegovy for adults with obesity or overweight with at least one weight-related condition in June 2021. FDA expanded the label to adolescents aged 12 years and older in December 2022. In March 2024, FDA approved Wegovy to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight. [1, 2]

How large is the Wegovy market?

Wegovy operates in the rapidly expanding anti-obesity medicine market, which includes GLP-1 and related incretin therapies. Market growth is being driven by high obesity prevalence, increased physician adoption, broader reimbursement discussions, and evidence linking weight loss to cardiovascular benefits.

Wegovy sales trajectory

Fiscal year	Wegovy sales	Reported growth or market context
2022	Approximately DKK 6 billion	Initial commercial ramp
2023	DKK 31.3 billion	Rapid expansion despite supply constraints
2024	Approximately DKK 58.2 billion	Continued volume growth and broader availability

Source: Novo Nordisk annual reports and company financial releases. [3, 4]

Novo Nordisk reported total 2024 revenue of approximately DKK 290.4 billion, with obesity-care products representing a major share of growth. Wegovy became the principal contributor to the company's obesity-care revenue, while Ozempic remained the larger product by total sales because of its diabetes market.

The product's revenue trajectory has been unusually steep for a prescription medicine. The major limiting factor has been manufacturing capacity rather than underlying demand.

What is the financial outlook for Wegovy?

The financial outlook remains positive, but growth rates are expected to moderate from the initial launch period.

Novo Nordisk's financial performance depends on four variables:

1. Volume growth as new production capacity comes online.
2. Net pricing after rebates and payer discounts.
3. Market share relative to Zepbound and other incretin therapies.
4. Expansion into cardiovascular, adolescent, and international indications.

The March 2024 cardiovascular indication materially increased Wegovy's addressable market. The SELECT cardiovascular-outcomes trial reported a 20% reduction in major adverse cardiovascular events in adults with obesity or overweight and established cardiovascular disease who received semaglutide compared with placebo. [5]

That result supports reimbursement arguments based on reduced cardiovascular events rather than weight loss alone. It also gives Novo Nordisk a stronger basis for positioning Wegovy within chronic disease management.

The main financial risks are slower prescription growth, payer exclusions, lower realized prices, discontinuation after initial weight loss, and competition from tirzepatide products. Novo Nordisk has also faced investor concerns that its valuation and production plans embed aggressive assumptions about long-term obesity-drug demand.

What revenue exposure does Novo Nordisk have to obesity drugs?

Obesity products are increasingly important to Novo Nordisk's consolidated results. The company's obesity portfolio includes Wegovy, Saxenda, and related semaglutide development programs. Wegovy is the principal growth asset, while Saxenda is an older daily liraglutide product facing greater competitive and pricing pressure.

The company's diabetes franchise remains larger, but obesity products have generated a disproportionate share of incremental revenue and investor interest. Any sustained deterioration in Wegovy growth would affect Novo Nordisk's sales-growth profile, manufacturing utilization, and valuation.

How does Wegovy compare with Zepbound and Ozempic?

Wegovy's closest commercial competitor is Eli Lilly's Zepbound, which contains tirzepatide. Ozempic contains semaglutide but is approved for type 2 diabetes, not general weight management.

Product	Active ingredient	Primary FDA indication	Dosing	Manufacturer	Competitive position
Wegovy	Semaglutide	Chronic weight management; cardiovascular-risk reduction in eligible adults	Weekly injection	Novo Nordisk	Leading obesity brand with cardiovascular-outcomes label
Zepbound	Tirzepatide	Chronic weight management	Weekly injection	Eli Lilly	Strong weight-loss efficacy and rapid market share gains
Ozempic	Semaglutide	Type 2 diabetes	Weekly injection	Novo Nordisk	Major diabetes franchise; frequent off-label obesity use
Saxenda	Liraglutide	Chronic weight management	Daily injection	Novo Nordisk	Older GLP-1 product with lower commercial momentum
Mounjaro	Tirzepatide	Type 2 diabetes	Weekly injection	Eli Lilly	Diabetes counterpart to Zepbound

Clinical-trial comparisons require caution because Wegovy and Zepbound were not established in a single head-to-head registration trial at launch. Separate trials reported substantial average weight loss for both products, with tirzepatide generally showing higher average weight reduction in its obesity studies. Trial populations, treatment duration, dose escalation, adherence, and study design differ. [6, 7]

Wegovy retains several strategic advantages:

• Earlier market entry in obesity.
• A cardiovascular-risk reduction indication.
• Established manufacturing and physician familiarity.
• A large clinical and real-world evidence base.
• Potential use across obesity, cardiovascular disease, and adolescent populations.

Zepbound has its own advantages:

• Strong weight-loss efficacy in clinical trials.
• Access to Eli Lilly's incretin manufacturing investments.
• A dual GIP and GLP-1 mechanism.
• Competitive pricing and payer contracting potential.

What patents protect Wegovy?

Wegovy is protected by a portfolio covering semaglutide, pharmaceutical compositions, dosage forms, administration regimens, and manufacturing technology. The core molecule is also used in Ozempic and Rybelsus, which means Novo Nordisk's patent strategy extends across multiple semaglutide products.

The most important protection is the semaglutide compound patent family. Public patent analyses commonly place U.S. protection for semaglutide and related claims in the early 2030s, with relevant international expiry dates varying by jurisdiction. Patent term adjustment, patent-term extension, pediatric exclusivity, claim scope, and Orange Book listings affect the practical entry date.

What is the expected Wegovy patent expiration date?

The core U.S. semaglutide patent estate is generally expected to provide protection into approximately 2031 or 2032, depending on the patent and claim being evaluated. European protection is commonly reported to run into approximately 2031. In some emerging markets, including China and India, core protection may expire earlier, often around 2026, subject to local patents and regulatory requirements.

Patent expiry should not be treated as a single global date. Different claims can expire at different times, and a generic applicant may challenge one patent while designing around another.

What formulations are protected by Wegovy patents?

Potentially relevant protection includes:

• Semaglutide as an active pharmaceutical ingredient.
• Aqueous injectable compositions.
• Stabilized peptide formulations.
• Dose-escalation and maintenance regimens.
• Pre-filled pen delivery systems.
• Manufacturing and purification processes.
• Specific methods of treating obesity or reducing body weight.

The commercial importance of formulation patents depends on whether they cover the product as marketed or only particular manufacturing or delivery configurations. A generic applicant may avoid a formulation claim while still challenging a compound or method-of-use patent.

What is the Orange Book status of Wegovy?

Wegovy is an FDA-approved small-molecule or peptide drug product rather than a biologic licensed under the Public Health Service Act. Its relevant patents may be listed in FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, where they meet FDA listing requirements.

Semaglutide products share portions of the same underlying patent estate, but the Orange Book record must be reviewed by product and strength. A patent listed for Ozempic or Rybelsus does not automatically establish the same listing or enforceability position for Wegovy.

The principal regulatory protection includes:

• New drug approval protection for the original semaglutide product.
• Label-based protection associated with approved obesity indications.
• Patent protection covering semaglutide and related formulations.
• Pediatric exclusivity where applicable.
• Cardiovascular indication claims that may create method-of-use barriers.

The commercial entry date will depend on the interaction between FDA exclusivity, listed patents, Paragraph IV litigation, and the scope of any generic applicant's certification.

When does Wegovy lose exclusivity?

Wegovy does not have one universal loss-of-exclusivity date. The practical sequence is likely to involve several stages:

Protection type	Approximate timing or status
U.S. core semaglutide patent protection	Generally expected into the early 2030s
European core protection	Generally expected into approximately 2031
Earlier expiry in selected markets	Potentially around 2026, subject to local rights
Regulatory exclusivity	Depends on the applicable semaglutide approval and indication
Formulation and manufacturing patents	May extend beyond or differ from compound protection
Generic entry	Dependent on litigation, settlement, approval, and commercial launch

U.S. generic entry could occur before nominal patent expiry if an applicant prevails in Paragraph IV litigation, reaches a settlement with Novo Nordisk, or launches after invalidating or circumventing relevant claims.

Which companies are challenging Wegovy patents?

No major FDA-approved generic competitor to Wegovy had entered the U.S. market as of the latest publicly available regulatory and company information used here. Publicly disclosed challenges have focused more heavily on compounded semaglutide, unauthorized compounded products, and broader patent disputes than on a commercially launched ANDA product.

Potential future challengers include large generic manufacturers with peptide manufacturing capabilities and companies developing semaglutide follow-on products. A Paragraph IV challenge would likely target the compound, formulation, or method-of-use patents listed for the relevant semaglutide product.

Novo Nordisk has filed litigation against compounding pharmacies, medical spas, and sellers of products represented as semaglutide. Those cases are separate from conventional ANDA Paragraph IV litigation and do not by themselves establish the timing of generic Wegovy entry. [8]

What generic entry risks exist for Wegovy?

The primary generic-entry risks are medium- to long-term rather than immediate.

Regulatory pathway

Semaglutide is a peptide drug, not a traditional antibody biologic. A follow-on applicant may pursue an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence, or a 505(b)(2) application if it relies partly on the reference product while introducing differences.

The regulatory pathway may be more difficult than for a conventional small molecule because semaglutide is a complex peptide with sensitive requirements for identity, purity, aggregation, device performance, and injection presentation.

Technical barriers

Manufacturing barriers include:

• Peptide synthesis and purification.
• Control of impurities and aggregation.
• Consistent high-volume sterile filling.
• Pen-device compatibility.
• Supply of active pharmaceutical ingredient.
• Stability through the product's shelf life.

A generic entrant must also secure sufficient production capacity. The market opportunity is large, but a limited-scale entrant may be unable to compete effectively against Novo Nordisk and Eli Lilly on supply, contracting, and distribution.

Legal barriers

Novo Nordisk can rely on multiple patent categories rather than a single compound claim. Even if an entrant invalidates one patent, remaining formulation, process, device, or method-of-use claims may delay launch or force a narrower label.

What patent litigation affects Wegovy?

The most visible legal activity has involved semaglutide compounding and counterfeit or unauthorized products. Novo Nordisk has pursued defendants that marketed compounded semaglutide or used Novo trademarks without authorization. The company has also challenged pharmacy and telehealth businesses over product quality, branding, and representations.

The legal risks for a future generic challenger will be different. An ANDA filing with a Paragraph IV certification could trigger a 30-month stay if Novo Nordisk files a timely infringement action under the Hatch-Waxman Act. Settlement terms could establish an agreed entry date, subject to antitrust review and FDA requirements.

As of the latest cited information, no publicly established settlement had set a definitive U.S. generic Wegovy launch date.

Does Wegovy face biosimilar risk?

Wegovy does not face biosimilar risk in the conventional legal sense because semaglutide is not an FDA-approved biologic. The more relevant threat is a generic or 505(b)(2) semaglutide product.

The technical risk can still resemble biologic competition in some respects. Semaglutide is a complex peptide, and manufacturing consistency may limit the number of credible entrants. Regulatory approval will not necessarily produce immediate commercial substitution if payers, physicians, and patients prefer the reference brand's device, supply reliability, or evidence base.

What manufacturing and supply barriers affect Wegovy?

Supply has been a central constraint on Wegovy's growth. Novo Nordisk has invested heavily in production expansion, including active ingredient, formulation, filling, and device capacity.

In 2024, Novo Nordisk announced an agreement under which Novo Holdings would acquire Catalent, followed by the acquisition of selected Catalent manufacturing sites by Novo Nordisk for approximately $11 billion. The transaction was intended to expand manufacturing capacity for current and future medicines, including high-demand injectable products. Regulatory authorities reviewed the transaction, and the structure raised competition and supply-chain questions. [9]

The capacity strategy is strategically important because the obesity market is supply constrained. More capacity should support unit growth, but it can also increase fixed costs and reduce the scarcity premium that has supported pricing.

What licensing deals support Wegovy?

Wegovy is primarily an internally owned Novo Nordisk product. Its commercial economics are not based on a major external license comparable to products developed through a co-commercialization agreement.

Novo Nordisk controls the semaglutide franchise, manufacturing strategy, trademarks, regulatory submissions, and core commercial infrastructure. External relationships are more relevant to contract manufacturing, logistics, device components, and research collaborations than to ownership of Wegovy itself.

What is the geographic coverage of Wegovy?

Wegovy is approved in the United States and multiple international markets, with launch timing varying by country. Geographic performance depends on regulatory approval, reimbursement, supply allocation, pricing controls, and local patent rights.

The United States remains the largest commercial market because of its high obesity prevalence, prescription volume, and willingness to pay among commercially insured patients. Access is more restricted where public reimbursement excludes anti-obesity drugs.

International markets provide long-term growth, but lower prices and government procurement can reduce revenue per patient. Earlier patent expiry in some countries may also create follow-on competition before U.S. or European entry.

How strong is the Wegovy patent estate?

Wegovy has a strong near-term patent position because the semaglutide franchise combines core molecule protection with formulation, delivery, manufacturing, and indication-related rights. Its weakness is that the same active ingredient is used across several products, creating a large commercial incentive for challengers.

Patent strength is highest where:

• Core compound claims remain valid and enforceable.
• Formulation claims cover the marketed injectable product.
• Generic substitution requires use of patented methods.
• Manufacturing complexity raises the cost of independent development.
• Novo Nordisk can enforce rights across multiple jurisdictions.

Patent strength is lower where:

• Compound protection expires earlier.
• Local patent examination narrowed claims.
• Generic applicants can design around delivery or formulation claims.
• Method-of-use patents do not block a skinny-label product.
• Compounded or alternative semaglutide products bypass conventional substitution rules.

What generic launch scenarios exist for Wegovy?

Three scenarios are commercially plausible:

1. Delayed entry after core patents expire in the early 2030s.
2. Earlier negotiated entry following Paragraph IV litigation and settlement.
3. Staggered international entry beginning in markets where core patents expire earlier.

A launch would likely begin with limited supply and selected strengths. Commercial uptake would depend on whether the entrant can match Novo Nordisk's pen device, production scale, payer contracts, and distribution.

Generic pricing could be materially below Wegovy's list price, but actual savings would depend on rebates and insurance coverage. Payers may use generic semaglutide to negotiate lower net prices across the obesity-drug class.

Key Takeaways

• Wegovy sales reached approximately DKK 58.2 billion in 2024, up sharply from DKK 31.3 billion in 2023.
• Novo Nordisk's obesity franchise remains a major source of corporate growth.
• The cardiovascular-risk reduction indication expands Wegovy's medical and reimbursement case.
• Zepbound is the principal competitive threat, particularly on average weight-loss efficacy and market share.
• Core U.S. semaglutide protection is generally expected into approximately 2031 or 2032.
• Wegovy faces generic, not conventional biosimilar, risk.
• No major generic Wegovy product had launched in the U.S. as of the latest cited information.
• Manufacturing capacity, payer access, net pricing, and treatment persistence will determine near-term growth.
• The Catalent transaction is central to Novo Nordisk's capacity expansion strategy.
• Future Paragraph IV litigation and settlements could establish an earlier generic-entry date.

FAQs

How much revenue does Wegovy generate for Novo Nordisk?

Wegovy generated approximately DKK 58.2 billion in 2024, compared with DKK 31.3 billion in 2023, according to Novo Nordisk's reported financial results.

Is Wegovy protected by the same patents as Ozempic?

Wegovy and Ozempic share the semaglutide active ingredient and portions of the underlying patent estate. Product-specific Orange Book listings, approved indications, formulations, and patent claims must be assessed separately.

Can a pharmacy legally compound Wegovy?

Compounding rules depend on FDA requirements, drug-shortage status, state pharmacy law, and the specific product. Unauthorized use of Novo Nordisk's trademarks or misrepresentation of compounded products can create separate legal exposure.

Will a generic Wegovy be automatically interchangeable with the branded product?

Not necessarily. FDA approval, therapeutic-equivalence designation, device presentation, and state substitution rules determine whether a follow-on product can be automatically substituted.

Could Wegovy lose market share even before generic entry?

Yes. Zepbound and future oral incretin therapies could reduce Wegovy's share through stronger efficacy, lower net pricing, simpler administration, improved supply, or broader payer coverage.

References

1. U.S. Food and Drug Administration. (2021). FDA approves new drug treatment for chronic weight management, first since 2014.
2. U.S. Food and Drug Administration. (2024). FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight.
3. Novo Nordisk A/S. (2024). Annual report 2023.
4. Novo Nordisk A/S. (2025). Annual report 2024.
5. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. The New England Journal of Medicine, 389(24), 2221-2232.
6. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989-1002.
7. Jastre boff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205-216.
8. Novo Nordisk A/S. (2024). Legal actions concerning counterfeit and compounded semaglutide products.
9. Novo Nordisk A/S. (2024). Novo Nordisk to acquire three Catalent fill-finish sites from Novo Holdings.

DrugChatter Q&A for WEGOVY

Does medicare cover wegovy for heart disease?
Can i take wegovy if i had pancreatitis 20 years ago?
Wegovy loss of exclusivity?
Patents for wegovy?
What is wegovy's cost compared to other medications?